Literature DB >> 1609858

Prevention of recurrent cholesteatoma: use of hydroxyapatite plates and composite grafts.

B Black1.   

Abstract

Recurrent cholesteatoma after closed techniques occurs in four patterns: (1) through an attic defect, (2) via erosions in the canal wall, (3) as a pars tensa invagination, and (4) as a borderline invagination between an attic defect repair and a normal pars tensa. Semicircular porous hydroxyapatite ceramic plates 7, 10, and 14 mm in diameter, and 1 mm thick are used as underlays to repair attic defects, supplemented by bone dust pate and fine tragal cartilage-perichondrium composite grafts. Pate and either the tragal composites or fine tragal cartilage shavings are used to minimize the risk of wall erosion pockets. Borderline invaginations and pars tensa recollapse are prevented with the fine tragal composites. The extent of pars tensa reinforcement is determined by the extent of disease. Care to anticipate and prevent each of the four patterns has produced a comprehensive reduction of recurrent cholesteatoma to acceptable levels (under 10%). Residual disease, found in 19 percent of second stage cases, has required open conversion in only 3 percent of cases. The above techniques therefore provide optimal results and are recommended as routine closed cavity techniques.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1609858

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  3 in total

1.  Reconstruction of outer attic wall defects using bone paté: Long-term clinical and histological evaluation.

Authors:  Andrea Bacciu; Enrico Pasanisi; Vincenzo Vincenti; Filippo Di Lella; Salvatore Bacciu
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-06-28       Impact factor: 2.503

Review 2.  Cholesteatoma: skin in the wrong place.

Authors:  J M Robinson
Journal:  J R Soc Med       Date:  1997-02       Impact factor: 5.344

3.  Analysis of long-term anatomic results of radical mastoidectomy.

Authors:  Horia Mocanu; Adela-Ioana Mocanu; Gabriella Coadă; Alexandru Bonciu; Mihai-Adrian Schipor; Marian Rădulescu
Journal:  Exp Ther Med       Date:  2021-12-17       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.